ReviewDrug delivery2017
Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy.
Review in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can vitamin E ester derivatives be excellent alternatives of vitamin E: state of art.Bioprocess and biosystems engineering · 2023Pooled it
- Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.International journal of pharmaceutics: X · 2026Review
- TPGS-stabilized pyrimethamine micelles promote ROS-associated apoptosis in MDA-MB-231 cells and suppress tumour progression in a murine lymphoma model.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Intravenous paclitaxel delivered by a vitamin E nanocarrier as a safe and economical alternative to albumin-bound nanoparticles.Discover oncology · 2026Article
- Engineered Lecithin-Polymer Hybrid Micelles for Enhanced Gallic Acid Delivery: Response Surface Optimization and Preclinical Evaluation.AAPS PharmSciTech · 2026Article
- Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy.Drug delivery · 2025Article
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Next-generation cancer nanotherapeutics: PluronicNaunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Novel PEGylated cholephytosomes for targeting fisetin to breast cancer: in vitro appraisal and in vivo antitumoral studies.Drug delivery and translational research · 2024Article
- Role of Vitamins in Therapeutic and Targeting Approaches for Prostate Cancer: An Overview.Current drug targets · 2024Review
- Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches.Current pharmaceutical biotechnology · 2024Review
- Synergistic effect of doxorubicin lauroyl hydrazone derivative delivered by α-tocopherol succinate micelles for the treatment of glioblastoma.International journal of pharmaceutics: X · 2023Article
- Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy.Drug delivery · 2023Article
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Formation, characterization, and analysis of curcumin nanoformulation for evaluating itsBiotechnologia · 2023Article
- Biological fate and interaction with cytochromes P450 of the nanocarrier material, d-Acta pharmaceutica Sinica. B · 2022Article
- An Oral 3D Printed PLGA-Tocopherol PEG Succinate Nanocomposite Hydrogel for High-Dose Methotrexate Delivery in Maintenance Chemotherapy.Biomedicines · 2022Article
- ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment.Materials today. Bio · 2022Article
- Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies.Drug delivery and translational research · 2022Article
- SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma.Journal of materials science. Materials in medicine · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains an obstacle to be surmounted by humans. As an FDA-approved biocompatible drug excipient, d-α-tocopheryl polyethylene glycol succinate (TPGS) has been widely applied in drug delivery system (DDS). Along with in-depth analyses of TPGS-based DDS, increasingly attractive results have revealed that TPGS is able to act not only as a simple drug carrier but also as an assistant molecule with various bio-functions to improve anticancer efficacy. In this review, recent advances in TPGS-based DDS are summarized. TPGS can inhibit P-glycoprotein, enhance drug absorption, induce mitochondrial-associated apoptosis or other apoptotic pathways, promote drug penetration and tumor accumulation, and even inhibit tumor metastasis. As a result, many formulations, by using original TPGS, TPGS-drug conjugates or TPGS copolymers, were prepared, and as expected, an enhanced therapeutic effect was achieved in different tumor models, especially in multidrug resistant and metastatic tumors. Although the mechanisms by which TPGS participates in such functions are not yet very clear, considering its effectiveness in tumor treatment, TPGS-based DDS appears to be one of the best candidates for future clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.